Exploration of the prognostic prediction value of the PANoptosis‐based risk score and its correlation with tumor immunity in lung adenocarcinoma

Abstract

AbstractLung adenocarcinoma (LUAD) is a common cancer with high mortality worldwide. PANoptosis is a novel inflammatory programmed cell death modality with the characteristics of pyroptosis, apoptosis and necroptosis. It is necessary to explore PANoptosis‐related genes in LUAD patients and offer evidence for prognosis prediction and therapeutic strategies. Single‐cell RNA sequencing data and RNA expression profiles of LUAD patients from The Cancer Genome Atlas and Gene Expression Omnibus databases are used to screen PANoptosis‐related differential genes for the construction of a risk model. Fifteen PANoptosis‐related markers with prognostic value were identified by Least Absolute Shrinkage and Selection Operator (LASSO)–Cox regression analysis. Kaplan–Meier analysis and receiver operating characteristic curve analysis further demonstrated the significant predictive capability. Immune infiltration, Single Nucleotide Variants (SNV) mutations, and clinical drug susceptibility were analyzed. In conclusion, a risk model of 15 PANoptosis‐related genes has significant value in prognostic prediction for LUAD and has potential to direct clinical therapeutic strategies during the treatment.